Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02

The activity of single-agent targeted molecular therapies in glioblastoma has been limited to date. The North American Brain Tumor Consortium examined the safety, pharmacokinetics, and efficacy of combination therapy with sorafenib, a small molecule inhibitor of Raf, vascular endothelial growth fact...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lee, Eudocia Q., Kuhn, John, Lamborn, Kathleen R., Abrey, Lauren, DeAngelis, Lisa M., Lieberman, Frank, Robins, H. Ian, Chang, Susan M., Yung, W. K. Alfred, Drappatz, Jan, Mehta, Minesh P., Levin, Victor A., Aldape, Kenneth, Dancey, Janet E., Wright, John J., Prados, Michael D., Cloughesy, Timothy F., Gilbert, Mark R., Wen, Patrick Y.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2012
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3499017/
https://ncbi.nlm.nih.gov/pubmed/23099651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nos264
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados